Richard J. Hawkins Buys 48,225 Shares of Savara Inc. (NASDAQ:SVRA) Stock

Savara Inc. (NASDAQ:SVRA - Get Free Report) Director Richard J. Hawkins acquired 48,225 shares of the business's stock in a transaction on Friday, June 20th. The shares were purchased at an average price of $2.04 per share, for a total transaction of $98,379.00. Following the purchase, the director now directly owns 115,466 shares of the company's stock, valued at $235,550.64. This represents a 71.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Savara Stock Performance

SVRA stock traded up $0.02 on Thursday, reaching $2.21. The company's stock had a trading volume of 768,180 shares, compared to its average volume of 1,304,814. Savara Inc. has a 52 week low of $1.89 and a 52 week high of $5.11. The company has a market capitalization of $381.98 million, a P/E ratio of -4.60 and a beta of 0.32. The firm has a fifty day moving average of $2.70 and a two-hundred day moving average of $2.80. The company has a debt-to-equity ratio of 0.20, a current ratio of 14.91 and a quick ratio of 14.91.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12). As a group, analysts predict that Savara Inc. will post -0.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Guggenheim reiterated a "buy" rating and set a $8.00 price target (down from $9.00) on shares of Savara in a research report on Wednesday, May 28th. Wells Fargo & Company dropped their price target on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 28th. HC Wainwright cut Savara from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $6.00 to $2.00 in a research report on Thursday, May 29th. Finally, Evercore ISI dropped their price target on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research report on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Savara has a consensus rating of "Moderate Buy" and an average price target of $7.17.

Hedge Funds Weigh In On Savara

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Savara by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock valued at $25,512,000 after purchasing an additional 365,959 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Savara by 24.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company's stock valued at $482,000 after purchasing an additional 31,168 shares in the last quarter. Millennium Management LLC boosted its stake in Savara by 71.8% during the 4th quarter. Millennium Management LLC now owns 482,263 shares of the company's stock valued at $1,481,000 after purchasing an additional 201,599 shares in the last quarter. Deutsche Bank AG boosted its stake in Savara by 6.1% during the 4th quarter. Deutsche Bank AG now owns 927,595 shares of the company's stock valued at $2,848,000 after purchasing an additional 53,054 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its stake in Savara by 314.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company's stock valued at $217,000 after purchasing an additional 53,547 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.